Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast
VRTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.38 / 5 from 32 analysts
- Price target
- $571.46 average of analyst targets
- Upside to target
- +14.4% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $4.35
- 52-week range
- $409.47 – $557.96
VRTX analyst ratings
32 analystsNumber of analysts at each rating.
VRTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VRTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.04 | −$29.51 | $5.25 | $4.80 | −99.2% | 15 |
| Current fiscal year (2026) | $17.83 | $4.52 | $19.54 | $18.40 | −3.1% | 17 |
| Next fiscal year (2027) | $20.39 | $17.86 | $22.89 | $17.83 | +14.3% | 17 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VRTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.43B | $3.32B | $3.50B | +11.4% | 16 |
| Current fiscal year (2026) | $13.27B | $13.16B | $13.38B | +10.6% | 19 |
| Next fiscal year (2027) | $14.56B | $13.89B | $15.23B | +9.8% | 17 |
VRTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VRTX revenue: reported and forecast
VRTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.90 | $4.91 | −$1.74 | −$0.74 | $0.04 | −99.3% | 2 up · 0 down |
| Current fiscal year (2026) | $19.03 | $19.05 | $16.02 | $16.35 | $17.83 | −6.3% | 2 up · 0 down |
| Next fiscal year (2027) | $21.50 | $21.80 | $20.13 | $20.22 | $20.39 | −5.2% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VRTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VRTX beat in 8 of 12.
What analysts expect from VRTX
32 analysts cover Vertex; their consensus rating is buy (4.38 on a 1–5 scale, where 5 is a strong buy). The average price target is $571.46, 14.4% above the latest close of $499.74. Analysts expect earnings of $17.83 per share for 2026, −3.1% from a year earlier. For 2027 the average estimate is $20.39 per share on revenue of $14.6 billion. Vertex beat the EPS estimate in 8 of the last 12 quarters.
Related: VRTX income statement, VRTX key metrics, VRTX chart. See the VRTX stock overview for the latest quote and news.
VRTX forecast FAQ
What is Vertex's price target?
The average analyst price target for Vertex is $571.46, 14.4% above the latest close of $499.74.
Is Vertex a buy, hold or sell?
Of 32 analysts covering Vertex, 20 rate it a strong buy, 6 a buy, 5 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vertex's EPS forecast?
Analysts forecast $17.83 per share for 2026 (range $4.52 to $19.54); for 2027 the estimate is $20.39.
What is Vertex's revenue forecast?
The average revenue estimate for 2026 is $13.3 billion, growth of 10.6%; for 2027 it is $14.6 billion.
When does Vertex report earnings?
Vertex is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $4.35.
Does Vertex usually beat earnings estimates?
Vertex reported EPS at or above the analyst estimate in 8 of the last 12 quarters.